The financial toxicity of pediatric cancers is real, not only to individuals, but also to the insurance system and society. For example, 800 neuroblastoma patients in the US are a $1.5 Billion industry, not including relapse, life-long complications, and complex outcomes (e.g. secondary cancers). A goal of new CCDI products should seek to improve outcomes at reduces costs. Collecting hospitalization and duration data would be important to better resolve these issues.